Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Urology Reports
Published in: Current Urology Reports 9/2019

01-09-2019 | Fertility | Men's Health (A Dabaja, Section Editor)

Non-oncologic Indications for Male Fertility Preservation

Authors: Heiko Yang, Joris Ramstein, James Smith

Published in: Current Urology Reports | Issue 9/2019

Login to get access

Abstract

Purpose of Review

To explore non-oncologic indications for male fertility preservation.

Recent Findings

Common scenarios in which male fertility could be irreversibly compromised include autoimmune conditions requiring treatment with cyclophosphamide, gender dysphoria prior to starting hormone therapy, military deployment, and critical illness. Fertility preservation should be considered with particular attention to the timing and logistics specific to each scenario.

Summary

Recognition and familiarity with such situations will help physicians provide better counseling to patients and their families, improve the quality of decision-making, and ultimately reduce missed opportunities and regret.
Literature
1.
Cooper GS, Stroehla BC. The epidemiology of autoimmune diseases. Autoimmun Rev. 2003;2(3):119–25.CrossRef
2.
Smith ZL, Werntz RP, Eggener SE. Testicular cancer: epidemiology, diagnosis, and management. Med Clin North Am. 2018;102(2):251–64.CrossRef
3.
Condorelli M, Demeestere I. Challenges of fertility preservation in non-oncological diseases. Acta Obstet Gynecol Scand. 2019;98(5):638–46.CrossRef
4.
Zakhem GA, Motosko CC, Mu EW, Ho RS. Infertility and teratogenicity after paternal exposure to systemic dermatologic medications: a systematic review. J Am Acad Dermatol. 2019;80(4):957–69.CrossRef
5.
Aguilar-Mahecha A, Hales BF, Robaire B. Chronic cyclophosphamide treatment alters the expression of stress response genes in rat male germ cells. Biol Reprod. 2002;66(4):1024–32.CrossRef
6.
Vernet P, Aitken RJ, Drevet JR. Antioxidant strategies in the epididymis. Mol Cell Endocrinol. 2004;216(1–2):31–9.CrossRef
7.
Wyrobek AJ, Schmid TE, Marchetti F. Relative susceptibilities of male germ cells to genetic defects induced by cancer chemotherapies. J Natl Cancer Inst Monogr. 2005;2005(34):31–5.CrossRef
8.
• Glen CD, Dubrova YE. Exposure to anticancer drugs can result in transgenerational genomic instability in mice. Proc Natl Acad Sci U S A. 2012;109(8):2984–8 Convincingly demonstrates in an animal model that cyclophosphamide can have a permanent teratogenic effect, strengthening the argument for fertility preserving before any treatment is initiated.CrossRef
9.
Tiseo BC, Bonfá E, Borba EF, Munhoz GA, Wood GJA, Srougi M, et al. Complete urological evaluation including sperm DNA fragmentation in male systemic lupus erythematosus patients. Lupus. 2019;28(1):59–65.CrossRef
10.
Currey HL, et al. Comparison of azathioprine, cyclophosphamide, and gold in treatment of rheumatoid arthritis. Br Med J. 1974;3(5934):763–6.CrossRef
11.
Meistrich ML, Wilson G, Brown BW, da Cunha MF, Lipshultz LI. Impact of cyclophosphamide on long-term reduction in sperm count in men treated with combination chemotherapy for Ewing and soft tissue sarcomas. Cancer. 1992;70(11):2703–12.CrossRef
12.
Paoli D, Rizzo F, Fiore G, Pallotti F, Pulsoni A, Annechini G, et al. Spermatogenesis in Hodgkin’s lymphoma patients: a retrospective study of semen quality before and after different chemotherapy regimens. Hum Reprod. 2016;31(2):263–72.PubMed
13.
Pavin NF, et al. Tribulus terrestris protects against male reproductive damage induced by cyclophosphamide in mice. Oxidative Med Cell Longev. 2018;2018:5758191.CrossRef
14.
Shabanian S, et al. The effects of vitamin C on sperm quality parameters in laboratory rats following long-term exposure to cyclophosphamide. J Adv Pharm Technol Res. 2017;8(2):73–9.PubMedPubMedCentral
15.
Aghaie S, Nikzad H, Mahabadi JA, Taghizadeh M, Azami-Tameh A, Taherian A, et al. Protective effect of combined pumpkin seed and ginger extracts on sperm characteristics, biochemical parameters and epididymal histology in adult male rats treated with cyclophosphamide. Anat Sci Int. 2016;91(4):382–90.CrossRef
16.
Wiepjes CM, Nota NM, de Blok CJM, Klaver M, de Vries ALC, Wensing-Kruger SA, et al. The Amsterdam Cohort of Gender Dysphoria Study (1972-2015): trends in prevalence, treatment, and regrets. J Sex Med. 2018;15(4):582–90.CrossRef
17.
Auer MK, Fuss J, Nieder TO, Briken P, Biedermann SV, Stalla GK, et al. Desire to have children among transgender people in Germany: a cross-sectional multi-center study. J Sex Med. 2018;15(5):757–67.CrossRef
18.
Wierckx K, van Caenegem E, Pennings G, Elaut E, Dedecker D, van de Peer F, et al. Reproductive wish in transsexual men. Hum Reprod. 2012;27(2):483–7.CrossRef
19.
Hamidi O, Davidge-Pitts CJ. Transfeminine hormone therapy. Endocrinol Metab Clin N Am. 2019;48(2):341–55.CrossRef
20.
Kent MA, Winoker JS, Grotas AB. Effects of feminizing hormones on sperm production and malignant changes: microscopic examination of post orchiectomy specimens in transwomen. Urology. 2018;121:93–6.CrossRef
21.
• Adeleye AJ, et al. Semen parameters among transgender women with a history of hormonal treatment. Urology. 2019;124:136–41 Shows that feminizing hormone therapy and short-term withdrawal of therapy have varying deleterious effects on semen analysis parameters.CrossRef
22.
Mattawanon N, Spencer JB, Schirmer DA, Tangpricha V. Fertility preservation options in transgender people: a review. Rev Endocr Metab Disord. 2018;19(3):231–42.CrossRef
23.
Returning home from Iraq and Afghanistan: assessment of readjustment needs of veterans, service members, and their families. Mil Med, 2014. 179(10): p. 1053–5.
24.
Nnamani NS, Janak JC, Hudak SJ, Rivera JC, Lewis EA, Soderdahl DW, et al. Genitourinary injuries and extremity amputation in Operations Enduring Freedom and Iraqi Freedom: early findings from the Trauma Outcomes and Urogenital Health (TOUGH) project. J Trauma Acute Care Surg. 2016;81(5 Suppl 2 Proceedings of the 2015 Military Health System Research Symposium):S95–9.CrossRef
25.
Machen GL, Harris SE, Bird ET, Brown ML, Ingalsbe DA, East MM, et al. Utilization of cryopreserved sperm cells based on the indication for storage. Investig Clin Urol. 2018;59(3):177–81.CrossRef
26.
Angus DC, Linde-Zwirble WT, Sirio CA, Rotondi AJ, Chelluri L, Newbold RC 3rd, et al. The effect of managed care on ICU length of stay: implications for Medicare. JAMA. 1996;276(13):1075–82.CrossRef
27.
Wu AW, Pronovost P, Morlock L. ICU incident reporting systems. J Crit Care. 2002;17(2):86–94.CrossRef
28.
Young MP, Birkmeyer JD. Potential reduction in mortality rates using an intensivist model to manage intensive care units. Eff Clin Pract. 2000;3(6):284–9.PubMed
29.
Hall MJ, Levant S, DeFrances CJ. Trends in inpatient hospital deaths: National Hospital Discharge Survey, 2000-2010. NCHS Data Brief. 2013;(118):1–8.
30.
Rothman CM. A method for obtaining viable sperm in the postmortem state. Fertil Steril. 1980;34(5):512.CrossRef
31.
Ethics Committee of the American Society for Reproductive Medicine. Electronic address, a.a.o. and M. Ethics Committee of the American Society for Reproductive. Fertility treatment when the prognosis is very poor or futile: an Ethics Committee opinion. Fertil Steril. 2019;111(4):659–63.CrossRef
32.
Rao JK, Anderson LA, Lin FC, Laux JP. Completion of advance directives among U.S. consumers. Am J Prev Med. 2014;46(1):65–70.CrossRef
33.
• Waler NJ, et al. Policy on posthumous sperm retrieval: survey of 75 major academic medical centers. Urology. 2018;113:45–51 A thorough examination of ethical considerations surrounding posthumous sperm retrieval with data from multiple academic centers. Shows that majority hospitals do not have a written policy.CrossRef
34.
Ravitsky V. Posthumous reproduction guidelines in Israel. Hast Cent Rep. 2004;34(2):6–7.
35.
Kerr SM, Caplan A, Polin G, Smugar S, O'Neill K, Urowitz S. Postmortem sperm procurement. J Urol. 1997;157(6):2154–8.CrossRef
36.
Ethics Committee of the American Society for Reproductive, M. Posthumous collection and use of reproductive tissue: a committee opinion. Fertil Steril. 2013;99(7):1842–5.CrossRef
Metadata
Title
Non-oncologic Indications for Male Fertility Preservation
Authors
Heiko Yang
Joris Ramstein
James Smith
Publication date
01-09-2019
Publisher
Springer US
Published in
Current Urology Reports / Issue 9/2019
Print ISSN: 1527-2737
Electronic ISSN: 1534-6285
DOI
https://doi.org/10.1007/s11934-019-0915-3

Other articles of this Issue 9/2019

Current Urology Reports 9/2019 Go to the issue

Benign Prostatic Hyperplasia (K McVary, Section Editor)

Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms: What Is the Role and Significance of Inflammation?

Pediatric Urology (D Weiss, Section Editor)

Ureteral Obstruction After Endoscopic Treatment of Vesicoureteral Reflux: Does the Type of Injected Bulking Agent Matter?

Prostate Cancer (S Prasad, Section Editor)

Hypofractionated Radiotherapy for Localized Prostate Cancer: When and for Whom?

Lower Urinary Tract Symptoms & Voiding Dysfunction (J Sandhu, Section Editor)

What Is New in Neuromodulation?

Lower Urinary Tract Symptoms & Voiding Dysfunction (J Sandhu, Section Editor)

Bladder Augmentation (Enterocystoplasty): the Current State of a Historic Operation

Men's Health (A Dabaja, Section Editor)

Artificial Intelligence in Reproductive Urology